CG400549 is a potential antibiotic candidate targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme in generating bacterial membrane) as it has novel chemical structure which has never been used as an antibacterial agent previously.
CG400549 is being developed to target the resistant bacterial strains including MRSA (Methicillin Resistant Staphylococcus aureus) and VRSA (Vancomycin Resistant Staphylococcus aureus), or commonly referred to as the ‘super bug.’
CG400549 has successfully completed the Phase I SAD study in Europe and has just received an approval for its Phase I MAD (Multiple Ascending Dose) study from the Ethics Committee.
The objective of the SAD study was to evaluate safety, tolerability and pharmacokinetic characteristics of CG400549 in healthy volunteers. The study demonstrated that CG400549 was safe and well tolerated among all subjects.
CrystalGenomics said that as the Ethics Committee has granted an approval for the MAD study, it is now planning to initiate the study which will further examine the safety and tolerability profiles of CG400549.
Joong Myung, president and CEO of CrystalGenomics, said: “We anticipate completing the MAD study and will make our transition into Phase IIa clinical trial by the end of this year.”